Search Results - "Partisano, Angela M."

Safety and efficacy of upfront plerixafor + G‐CSF versus placebo + G‐CSF for mobilization of CD34+ hematopoietic progenitor cells in patients ≥60 and <60 years of age with non‐Hodgkin's lymphoma or multiple myeloma by Micallef, Ivana N., Stiff, Patrick J., Stadtmauer, Edward A., Bolwell, Brian J., Nademanee, Auayporn P., Maziarz, Richard T., Partisano, Angela M., Marulkar, Sachin, DiPersio, John F.

“…The efficacy and safety of plerixafor + G‐CSF in enhancing hematopoietic stem cell mobilization and collection has been demonstrated in two phase III studies…”
Get full text

Utility of Genetic Testing to Identify Individuals Suspected of Having Hereditary ATTR (hATTR) Amyloidosis (P1.448) by Mora, Jordanna, Truty, Rebecca, Malladi, Ruthvik, Cheng, Nathan, Partisano, Angela M.

“…Abstract only…”
Get full text

A clinical review of montelukast in the treatment of seasonal allergic rhinitis by Gonyeau, Michael J, Pa

“…Seasonal allergic rhinitis is a disease characterized by sneezing, nasal congestion, rhinorrhea, and itching, conventionally treated with intranasal…”
Get full text

Impact of Patisiran on Overall Health Status in hATTR Amyloidosis: Results from the APOLLO Trial (S27.007) by Ajroud-Driss, Senda, Adams, David, Coelho, Teresa, Polydefkis, Michael, Gonzalez-Duarte, Alejandra, Quan, Dianna, Kristen, Arnt, Berk, John L., Partisano, Angela M., Gollob, Jared, Sweetser, Marianne T., Chen, Jihong, Agarwal, Sonalee, Suhr, Ole B.

“…Abstract only…”
Get full text

NT-proBNP Levels in Patients with Hereditary Transthyretin-mediated Amyloidosis Treated in the Phase 3 APOLLO Study Based on Diuretic Use by Grogan, Martha, Adams, David, Coelho, Teresa, Kristen, Arnt, Dispenzieri, Angela, Solomon, Scott, Gollob, Jared, Goyal, Sunita, Partisano, Angela M., Chen, Jihong, Vest, John, Suhr, Ole B.

“…Hereditary transthyretin-mediated (hATTR) amyloidosis is a rare, multisystem, rapidly progressive, life-threatening disease caused by a mutation in the TTR…”
Get full text

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Preliminary Phase 1/2 Study Results in Patients with PNH by Hill, Anita, Gaya Valls, Anna, Griffin, Morag, Munir, Talha, Borodovsky, Anna, Kawahata, Nori, Mclean, Helen, Shi, Kelvin, Partisano, Angela M., Kim, Jae, Najafian, Nader, Urbano, Alvaro

“…▪ Background:Uncontrolled complement activation plays a pivotal role in a variety of disorders such as paroxysmal nocturnal hemoglobinuria (PNH). Challenges to…”
Get full text

Risk of Wernicke’s Encephalopathy in Patients with Myeloproliferative Neoplasm by Wu, Jasmanda, Mirza, Nadeem, Partisano, Angela M., Gallagher, Christina, Vaze, Anjali, Zhang, Ling, Gallagher, Meghan, Lin, Stephen, Juhaeri, Juhaeri

“…Background :Wernicke’s encephalopathy (WE) is an acute neuropsychiatric syndrome resulting from thiamine deficiency. This neurological deterioration is…”
Get full text

Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients with Inhibitors by Pasi, K John, Georgiev, Pencho, Mant, Tim, Lissitchkov, Toshko, Creagh, Michael Desmond, Bevan, David, Austin, Steve, Hay, Charles R, Hegemann, Inga, Kazmi, Rashid, Chowdary, Pratima, Ragni, Margaret V., Soh, Chang-Heok, Akinc, Akin, Partisano, Angela M., Sorenson, Benny, Rangarajan, Savita

“…Background: Development of inhibitory antibodies, also known as "inhibitors," to replacement factor is considered the most serious unmet need in hemophilia and…”
Get full text

Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients without Inhibitors by Ragni, Margaret V., Georgiev, Pencho, Mant, Tim, Creagh, Michael Desmond, Lissitchkov, Toshko, Bevan, David, Austin, Steve, Hay, Charles R, Hegemann, Inga, Kazmi, Rashid, Chowdary, Pratima, Rangarajan, Savita, Soh, Chang-Heok, Akinc, Akin, Partisano, Angela M., Sorenson, Benny, Pasi, K John

“…Background: Hemophilia is a bleeding disorder characterized by a profound defect in the ability to generate sufficient thrombin for effective hemostasis…”
Get full text

Safety and Efficacy of Upfront Plerixafor + G-CSF vs. Placebo + G-CSF for Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients ≥60 and <60 Years of Age with Non-Hodgkin’s Lymphoma or Multiple Myeloma by Micallef, Ivana N., Stiff, Patrick J., Stadtmauer, Edward A., Bolwell, Brian J., Nademanee, Auayporn P., Maziarz, Richard T., Partisano, Angela M., Marulkar, Sachin, DiPersio, John F.

“…The efficacy and safety of plerixafor + G-CSF in enhancing hematopoietic stem cell mobilization and collection has been demonstrated in two phase III studies…”
Get full text